AstraZeneca PLC (NASDAQ:AZN) Shares Bought by FSM Wealth Advisors LLC

FSM Wealth Advisors LLC lifted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 3.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,342 shares of the company’s stock after acquiring an additional 204 shares during the quarter. FSM Wealth Advisors LLC’s holdings in AstraZeneca were worth $424,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. AQR Capital Management LLC increased its position in shares of AstraZeneca by 112.4% during the second quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock worth $1,067,000 after purchasing an additional 7,241 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in AstraZeneca by 38,185.0% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 53,599 shares of the company’s stock worth $4,180,000 after acquiring an additional 53,459 shares in the last quarter. Centaurus Financial Inc. purchased a new position in AstraZeneca in the 2nd quarter valued at approximately $182,000. GAMMA Investing LLC increased its stake in shares of AstraZeneca by 19.5% during the third quarter. GAMMA Investing LLC now owns 5,433 shares of the company’s stock worth $423,000 after buying an additional 887 shares during the period. Finally, Fulton Bank N.A. raised its stake in AstraZeneca by 2.3% in the third quarter. Fulton Bank N.A. now owns 9,329 shares of the company’s stock valued at $727,000 after buying an additional 211 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Trading Down 0.7 %

Shares of AZN opened at $70.76 on Monday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $219.43 billion, a price-to-earnings ratio of 33.86, a P/E/G ratio of 1.18 and a beta of 0.46. The stock’s 50-day moving average price is $67.08 and its 200 day moving average price is $73.89.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.87 EPS. As a group, research analysts predict that AstraZeneca PLC will post 4.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, AstraZeneca has an average rating of “Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.